The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...

The FDA has expanded the approval of Valtoco (diazepam nasal spray) to include treatment of seizure clusters in patients aged 2 to 5 years.

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...

Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as "acute repetitive ...

The Food and Drug Administration (FDA) has expanded the approval of Valtoco ® (diazepam nasal spray) to include the ... prolonged central nervous system depression has been observed with diazepam.

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

We published the book "Demystifying Psychiatry" in 2010. Although basic principles of psychiatric treatment remain unchanged, ...